ClinicalTrials.gg
CompletedNCT01764854Updated Aug 10, 2020Results posted

Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis

A Phase 2 interventional study of AZD1722 (in-patient) and Placebo (in-patient) in End Stage Renal Disease, Chronic Kidney Disease Stage 5 and ESRD, sponsored by Ardelyx. Completed at 3 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-08-10.

Sponsored by Ardelyx · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 97 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.

Enrollment
235th of 638
88 · median 48
Started
2013
with 37 others
Phase 2
87 of 765
4 open now
Registered
307th of 765
by date

Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 235th largest by enrollment of the 638 interventional ones that give a count, is one of 38 that started in 2013, is one of 87 in phase 2, and was the 307th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 765 studies in Kidney Failure, Chronic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing fluid overload/weight gain between dialysis sessions for patients with End Stage Renal Disease on Hemodialysis.

Read the detailed description

This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacodynamics of the study drug in male and female patients with end-stage renal disease on hemodialysis. The study consists of a 2 week treatment-free run-in period where entry criteria are verified, a 4-week treatment period, of which the first week of treatment will be performed as an in-patient study in a clinical pharmacology unit (CPU) and the remaining three weeks of treatment will performed as an out-patient study, and a 2-week treatment-free follow-up period.

Safety assessments will be performed at regular intervals and will include clinical and vital signs, clinical laboratory evaluations, ECGs, and AE monitoring. Pharmacodynamic assessments will include, but are not limited to, interdialytic weight gain (IDWG), blood pressure, and stool sodium excretion. Pharmacokinetic assessments will include blood sampling for measurement of study drug plasma concentrations.

03

Conditions studied

  • End Stage Renal Disease
  • Chronic Kidney Disease Stage 5
  • ESRD

Keywords

  • Hemodialysis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females aged 18 to 80 years, inclusive;
  • between 18 and 45 kg/m2, inclusive;
  • Ambulatory (≥ 6 months) maintenance hemodialysis;
  • Stable dialysis treatment regimen 3x/week for ≥ 2 months prior to screening visit.

Exclusion criteria

Exclusion Criteria:

  • Currently taking diuretic medication;
  • Has a urine production of ≥ 200 ml/day (based on a 24-hour measurement starting on Day -1 and completed prior to randomization);
  • Predialysis systolic BP >200 mmHg or diastolic BP >110 mmHg on two successive occasions during the 2-week run-in period;
  • Predialysis SBP \< 110 mmHg on two successive occasions during the 2-week run-in period
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    AZD1722- in patient

    Tenapanor administered in a clinical pharmacology unit

    Drug: AZD1722 (in-patient)

  • Placebo comparator
    Placebo- in patient

    Placebo (size and color matched to experimental drug) administered in a clinical pharmacology unit

    Drug: Placebo (in-patient)

  • Experimental
    AZD1722 out-patient

    Tenapanor

    Drug: AZD1722 (out-patient)

  • Experimental
    Placebo out-patient

    Placebo

    Drug: Placebo

Interventions

  • doses between 5 and 60 mg BID may be administered based on tolerability in a CPU setting

    Also known as: RDX5791, Tenapanor

  • DrugPlacebo (in-patient)

    Placebo, size and color matched to experimental drug administered in a CPU

  • doses between 5 and 45 mg BID

    Also known as: Tenapanor

  • DrugPlacebo

    Placebo, size and color matched to experimental drug

06

What researchers measure

Primary outcomes

  1. Change in Mean Weekly Interdialytic Weight Gain (IDWG)

    Patients are weighed pre dialysis prior to their first dialysis of the week. This measure looks at the change in pre-dialysis weight over time

    Time frame: Run-in period (Weeks -2 and -1) versus Week 4 (end of treatment)

Secondary outcomes

  1. Stool Sodium Content

    The amount of sodium in a days worth of stool output

    Time frame: Days 1 through 7

07

Results

Posted Aug 10, 2020

Participant flow

Participant flow — Overall Study
MilestoneAZD1722- in PatientPlacebo- in PatientAZD1722 Out-patientPlacebo Out-patient
Started883735
Completed883133
Not completed0062
Withdrew: Adverse event0020
Withdrew: Withdrawal by subject0010
Withdrew: Relocation0020
Withdrew: Protocol violation0012

Outcome measures

PrimaryChange in Mean Weekly Interdialytic Weight Gain (IDWG)

Patients are weighed pre dialysis prior to their first dialysis of the week. This measure looks at the change in pre-dialysis weight over time

Time frame:
Run-in period (Weeks -2 and -1) versus Week 4 (end of treatment)
Reported as:
Mean · kilograms
Change in Mean Weekly Interdialytic Weight Gain (IDWG)
kilogramsAZD1722 Out-patientPlacebo Out-patient
Change in Mean Weekly Interdialytic Weight Gain (IDWG)-0.26 ± 0.939-0.23 ± 0.871
Statistical analysis
  • AZD1722 Out-patient vs Placebo Out-patient · ANCOVA · p = 0.46
SecondaryStool Sodium Content

The amount of sodium in a days worth of stool output

Time frame:
Days 1 through 7
Reported as:
Mean · mEq/day
Stool Sodium Content
mEq/dayAZD1722- in PatientPlacebo- in Patient
Stool Sodium Content36.62 ± 21.8092.82 ± 2.655
Statistical analysis
  • AZD1722- in Patient vs Placebo- in Patient · t-test, 2 sided · p = <0.0001

Adverse events

Collected over one month. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AZD1722- in Patient0/8 (0%)0/8 (0%)6/8 (75%)
Placebo- in Patient0/8 (0%)3/8 (37.5%)2/8 (25%)
AZD1722 Out-patient0/37 (0%)2/37 (5.4%)3/37 (8.1%)
Placebo Out-patient0/35 (0%)1/35 (2.9%)21/35 (60%)
Most frequent serious events
Most frequent serious events
EventAZD1722- in PatientPlacebo- in PatientAZD1722 Out-patientPlacebo Out-patient
SyncopeCardiac disorders0/81/81/370/35
acute respiratory failureRespiratory, thoracic and mediastinal disorders0/81/80/370/35
local swellingNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/81/80/370/35
pneumoniaRespiratory, thoracic and mediastinal disorders0/80/80/371/35
Urinary Tract InfectionRenal and urinary disorders0/80/81/370/35
Most frequent other events
Most frequent other events
EventAZD1722- in PatientPlacebo- in PatientAZD1722 Out-patientPlacebo Out-patient
diarrheaGastrointestinal disorders6/82/83/3721/35

Baseline characteristics

Age, Continuous
Age, Continuous(years)AZD1722- in PatientPlacebo- in PatientAZD1722 Out-patientPlacebo Out-patientTotal
Mean47.9 ± 8.354.4 ± 6.551.5 ± 11.549.3 ± 11.850.6 ± 11.6
Sex: Female, Male
Sex: Female, Male(Participants)AZD1722- in PatientPlacebo- in PatientAZD1722 Out-patientPlacebo Out-patientTotal
Female23131533
Male65242055
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AZD1722- in PatientPlacebo- in PatientAZD1722 Out-patientPlacebo Out-patientTotal
Hispanic or Latino10131024
Not Hispanic or Latino78242564
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AZD1722- in PatientPlacebo- in PatientAZD1722 Out-patientPlacebo Out-patientTotal
American Indian or Alaska Native00101
Asian00303
Native Hawaiian or Other Pacific Islander00000
Black or African American66141945
White22181638
More than one race00000
Unknown or Not Reported00101
Height
Height(centimeters)AZD1722- in PatientPlacebo- in PatientAZD1722 Out-patientPlacebo Out-patientTotal
Mean172.89 ± 9.31172.05 ± 16.48170.23 ± 10.80170.20 ± 10.39170.63 ± 10.84
08

Study locations

3 sites
  • Southwest Clinical Research Institute
    Tempe, Arizona 85284, United States
  • Denver Nephrology
    Denver, Colorado 80230, United States
  • DaVita Clinical Research
    Minneapolis, Minnesota 55404, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2020, 6 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2013
First posted
Jan 10, 2013
Start
Jan 2013
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results first posted
Aug 10, 2020
Last update
Aug 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01764854
Lead sponsor
Ardelyx
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Jan 10, 2013
Start date
Jan 2013
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Aug 10, 2020
Last update
Aug 10, 2020

Study contacts

David P Rosenbaum, PhD
study director · Ardelyx, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenapanor

Start the discussion